Diagnosis and treatment of sarcoma of the uterus. A review

Tropé, Claes G.; Abeler, Vera M.; Kristensen, Gunnar B.

doi:10.3109/0284186x.2012.689111

Cited by 171 publications

(176 citation statements)

References 79 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…While adjuvant pelvic radiotherapy may be used to reduce the risk of local recurrences, systemic recurrences and metastatic disease may be prevented with chemotherapy. However, the effectiveness of any form of adjuvant treatment on survival has not been consistently shown (1,12). In a Gynecologic Oncology Group (GOG) study, 156 patients with stage I (disease limited to corpus) or stage II (disease limited to the corpus and cervix) uterine sarcomas were evaluated in a randomized study.…”

Section: Discussionmentioning

confidence: 99%

“…Five-year disease-specific survival for patients with stage I and II disease is 51% and 25%, respectively. For all stages of patients with LMS of the uterus, 5-year disease specific survival is only 32% (1,6).…”

Section: Introductionmentioning

confidence: 99%

“…This malignancy is a highly aggressive tumor compared with other uterine cancers and it is associated with a significant risk of recurrence and death, even in early stages (1,2).…”

Section: Introductionmentioning

confidence: 99%

“…However, debulking of any tumor outside the uterus should be a goal of the surgery since the most important prognostic factor is residual disease following primary surgery (1,4).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of adjuvant treatment on oncologic outcomes inpatients with stage I leiomyosarcoma of the uterus

et al. 2017

View full text Add to dashboard Cite

Background/aim: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomyosarcoma (LMS).Materials and methods: Clinicopathological data of cases of stage I uterine LMS from 1998 to 2015 were retrieved from the computerized database of Hacettepe University Hospital. The Kaplan-Meier method was used to estimate survival and progression-free survival, and survival differences were analyzed by log-rank test. Cox regression analysis was performed to account for the potential influence of confounding factors. Results:We evaluated the outcomes of 35 patients with histologically proven stage I LMS. The median age at diagnosis was 50 years. All patients underwent surgical treatment and 20 patients (57.1%) received adjuvant therapy. Twelve of these patients (34.3%) received adjuvant chemotherapy, 3 (8.6%) received adjuvant pelvic irradiation, and 5 (14.2%) received adjuvant chemotherapy with pelvic irradiation. The median follow-up duration was 34 months (range: 3-231 months). Twenty-three (65.7%) patients had a recurrence during follow-up. Adjuvant therapy did not significantly improve median progression-free survival or median overall survival. Cox regression analysis did not demonstrate any significant impact of the factors studied, including age, menopausal status, tumor size, mitotic count, staging surgery, or adjuvant therapy. Conclusion:Adjuvant therapy for surgically treated stage I uterine LMS did not improve oncologic outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…This malignancy is a highly aggressive tumor compared with other uterine cancers and it is associated with a significant risk of recurrence and death, even in early stages (1,2).…”

Section: Introductionmentioning

confidence: 99%

“…However, debulking of any tumor outside the uterus should be a goal of the surgery since the most important prognostic factor is residual disease following primary surgery (1,4).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of adjuvant treatment on oncologic outcomes inpatients with stage I leiomyosarcoma of the uterus

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Vascular invasion is the only statistically significant prognostic factor, with 5 year survival rates of 83% and 17% in the absence and presence of vascular invasion, respectively. 11,12 Adenosarcomas consist of benign epithelial components and homologous or heterologous mesenchymal sarcomatous components; they are more common in postmenopausal women. However, these tumors can also occur in adolescents and young adults, and they comprise 5.5 to 9.0% of all uterine sarcomas.…”

Section: Histological Classification Of Uterine Sarcomasmentioning

confidence: 99%

Clinical and molecular features of uterine sarcomas

Almeida¹,

Cunha²,

Maciel³

et al. 2014

Medical Express

View full text Add to dashboard Cite

INTRODUCTION: Uterine sarcomas are rare forms of malignant neoplasm, comprising about 3% of all malignant uterine tumors, representing less than 1% of all gynecologic malignancies. Low cure rates often occur due mainly to distant metastases, usually to the lungs. Aggressiveness, high rates of local recurrence, distant metastasis and poor prognosis with overall two-year survival less than 50% are common features of uterine sarcomas. Despite the low prevalence, these tumors are of great interest because of their multiple morphological and clinical features. OBJECTIVE: This article will be focused on the uterine sarcomas general aspects, etiology, prognosis, treatment and molecular features. METHOD: This review was performed using the Pubmed database to search for published articles. RESULTS: Little is known about the etiology of uterine sarcomas. Some studies have demonstrated the association between genetic events involving mutations in genes of the cell cycle and apoptosis and epigenetic in gynecologic sarcomas. Previous studies showed that chromosomal translocations have been identified, resulting in fusion genes that are constitutive and might involve the activation of transcription factors. Advances in molecular techniques have improved the diagnostic possibilities and allowed an improved understanding of the various pathologies. CONCLUSIONS: There are several factors that make the study of sarcomas a challenging issue, since those tumors are rare and the cell origin of each histologic type is nor well known Thus, molecular study of the events involved in the development of different types of cancer may lead to new strategies used in the diagnosis and treatment of these tumors.

show abstract